GlassScriptPhysician profile
Ikumi Suzuki
NPI 1457679458
$4,990.28
in general payments reported to CMS, 2019-2025
41 companies · $148 in 2025
The $148 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $791 · 2020: $319 · 2021: $686 · 2022: $865 · 2023: $1,711 · 2024: $471 · 2025: $148.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,133 · Education: $197.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,132.83 |
| Education | $196.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $721.48 | 2019-2025 | Opdivo, Reblozyl |
| Janssen Biotech, INC. | $380.63 | 2019-2024 | Tecvayli |
| Daiichi Sankyo INC. | $347.44 | 2019-2024 | Enhertu, Injectafer |
| Glaxosmithkline, LLC. | $255.58 | 2021-2025 | Zejula, Jemperli |
| Merck Sharp & Dohme LLC | $243.56 | 2019-2024 | Keytruda, Lynparza, Welireg |
| Seagen INC. | $223.31 | 2019-2023 | Padcev, Tukysa, Adcetris |
| Eisai INC. | $201.79 | 2019-2025 | |
| Abbvie INC. | $201.38 | 2019-2024 | Venclexta |
| Amgen INC. | $179.60 | 2019-2023 | Lumakras, Xgeva, Vectibix |
| Astellas Pharma US INC | $170.61 | 2022-2023 | Xtandi, Xospata, Padcev |
| Pharmacyclics LLC, An Abbvie Company | $169.67 | 2021-2023 | Imbruvica, Epkinly |
| Taiho Oncology, INC. | $169.02 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $160.59 | 2022-2024 | Calquence, Enhertu, Lynparza |
| Veran Medical Technologies, INC. | $158.44 | 2019 | |
| Pfizer INC. | $134.20 | 2019-2024 |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $114.10 | 2022-2023 | Lunsumio, Phesgo, Perjeta |
| Mirati Therapeutics, INC. | $109.63 | 2023 | Krazati |
| Lilly USA, LLC | $103.41 | 2020-2023 | Jaypirca, Retevmo, Verzenio |
| Gilead Sciences, INC. | $88.93 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $86.47 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $82.94 | 2020-2023 | Xarelto |
| Aveo Pharmaceuticals, INC. | $81.47 | 2023 | Fotivda |
| Exelixis INC. | $52.58 | 2022-2023 | Cabometyx |
| Array Biopharma INC | $44.98 | 2023 | Xalkori, Lorbrena, Comirnaty |
| Genzyme Corporation | $44.06 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $43.95 | 2019-2024 | Alunbrig |
| Puma Biotechnology, INC. | $42.09 | 2019-2020 | |
| Organon LLC | $40.39 | 2022-2023 | Ontruzant |
| Tesaro, INC. | $37.51 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $34.83 | 2021-2023 | Libtayo |
| Agios Pharmaceuticals, INC. | $33.86 | 2019-2020 | |
| Celgene Corporation | $32.29 | 2019-2020 | |
| Pharmaessentia USA Corporation | $31.35 | 2024 | Besremi |
| Deciphera Pharmaceuticals INC. | $27.21 | 2020 | |
| Immunogen, INC. | $23.87 | 2023 | Elahere |
| Kite Pharma, INC. | $22.10 | 2023 | Yescarta |
| Incyte Corporation | $21.41 | 2020 | |
| Clovis Oncology, INC. | $20.67 | 2020 | |
| Rigel Pharmaceuticals, INC. | $20.57 | 2021 | |
| Eusa Pharma (US) LLC | $19.63 | 2021 | |
| Dova Pharmaceuticals | $12.68 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ikumi Suzuki listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.